Tesamorelin Dosage: What the Research Shows for Body Composition

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• The only FDA-approved tesamorelin dose is 2 mg subcutaneous once daily, for HIV-associated lipodystrophy. There is no approved bodybuilding indication.
• Tesamorelin is a 44-amino-acid analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary to release endogenous growth hormone in pulsatile fashion.
• In the published HIV trials, 2 mg/day for 26 weeks reduced visceral adipose tissue by 15.2% and raised IGF-1 by about 80% (Falutz et al., NEJM 2007).
• "Bodybuilding doses" reported online (1 to 2 mg/day, sometimes split twice daily) are extrapolations from FDA-approved use, not from controlled performance studies.
• Tesamorelin is a Schedule IV controlled substance only in select jurisdictions and is a regulated peptide; off-label or non-prescribed use carries legal and medical risks.

Direct answer (40-60 words, snippet-optimized)

The only FDA-approved tesamorelin dose is 2 mg subcutaneous daily, for HIV-associated visceral fat reduction. There is no FDA-approved or clinically validated bodybuilding dose. Online protocols typically extrapolate the 2 mg/day dose, sometimes split into two 1 mg injections, but no controlled trials exist for muscle gain or fat loss in healthy adults.

Table of contents

1. The 30-second answer
2. What tesamorelin is
3. The only FDA-approved dose
4. Why bodybuilders are interested
5. Reported off-label dosing patterns
6. What the body composition data actually shows
7. Side effects and IGF-1 elevation risk
8. Tesamorelin vs other GH secretagogues
9. Legal status and regulation
10. Bloodwork to monitor
11. FAQ
12. Sources
13. Footer disclaimers

What tesamorelin is

Tesamorelin is a synthetic 44-amino-acid peptide analog of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on the anterior pituitary and stimulates the pituitary to release endogenous human growth hormone (hGH) in the body's natural pulsatile pattern, mostly during sleep.

The molecule was developed by Theratechnologies and approved by the FDA in 2010 under the brand name Egrifta for one specific use: reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The lipodystrophy in this population, partly caused by older antiretroviral regimens, produced a recognizable pattern of visceral fat accumulation that responded poorly to diet and exercise. Tesamorelin's approval came after the Falutz trials in 2007 and 2010 showed durable visceral fat reduction.

Tesamorelin differs from synthetic hGH (somatropin) in two important ways. First, it works upstream by triggering the pituitary, not by replacing hGH directly, so the body's natural feedback loops still control the magnitude of the response. Second, the GH release stays pulsatile, which more closely resembles physiological secretion than the steady-state elevation produced by exogenous hGH injections.

For people interested in body composition outcomes, this upstream mechanism is what gives tesamorelin its appeal. The promise is GH-like effects with a lower side effect ceiling than direct hGH use. The reality is more complicated.

The only FDA-approved dose

The FDA-approved tesamorelin dose is 2 mg subcutaneous injection once daily, given preferentially in the morning. The injection sites rotate through the abdomen, away from the navel and away from any active scar tissue.

This dose is the basis for every published efficacy and safety study. Falutz et al. (NEJM 2007) used 2 mg/day for 26 weeks and showed a 15.2% reduction in visceral adipose tissue (VAT) versus a 5% increase in placebo. The follow-on Falutz et al. (J Clin Endocrinol Metab 2010) extended observation to 52 weeks; patients who continued tesamorelin maintained their VAT reduction, while patients who switched to placebo regained much of what they'd lost.

The 2 mg dose was selected during dose-ranging trials. Lower doses produced smaller IGF-1 increases and weaker VAT reduction. Higher doses (4 mg/day) didn't improve outcomes meaningfully and produced more IGF-1 elevation, which increases theoretical risks. So the FDA approved 2 mg/day, every day, indefinitely, with the understanding that benefit is lost if the medication is discontinued.

Why bodybuilders are interested

The interest in tesamorelin among bodybuilders, recreational lifters, and physique athletes comes from a hypothesis chain rather than a research finding:

1. Tesamorelin raises endogenous GH and IGF-1.
2. GH and IGF-1 are anabolic and lipolytic in adults.
3. Therefore tesamorelin should improve body composition (more lean mass, less fat) in healthy trained individuals.

Steps 1 and 2 are well-established. Step 3 has not been demonstrated in controlled trials in healthy adults. The HIV-lipodystrophy population studied for FDA approval has a baseline visceral fat phenotype that's quite different from a 25-year-old amateur powerlifter's body composition. Visceral fat (the deep belly fat around organs) responds more to GH-axis intervention than subcutaneous fat. A lean trained individual has very little VAT to begin with, so the marquee effect of tesamorelin in trials may not translate to the same magnitude in a healthy lifter.

The HIV trial population also lost an average of about 1 kg of total body weight, mostly from visceral fat, with no statistically significant change in subcutaneous fat or lean mass. That's a meaningful but not dramatic body composition shift, and it's the strongest data point that exists.

Reported off-label dosing patterns

Bodybuilding forums and underground guides describe several off-label dosing patterns for tesamorelin. None of these have been evaluated in controlled studies, and FormBlends does not endorse them. They're listed here for educational accuracy:

Reported pattern	Daily dose	Timing	Cited rationale
Standard	2 mg/day	AM, single injection	Mirror FDA-approved protocol
Split	1 mg AM + 1 mg PM	Twice daily	Two GH pulses instead of one
Pre-workout	1 to 2 mg	30 to 60 min pre-training	Time GH peak with training
Pre-bed	1 to 2 mg	Within 1 hr of sleep	Stack with natural nocturnal GH pulse
Cycle off-on	2 mg/day for 12 weeks, 4 weeks off	Continuous within cycles	Reduce IGF-1 ceiling effects

A few important caveats. The split-dose protocol's claim about "two pulses" oversimplifies how GH pulsatility works. The pituitary's response to GHRH stimulation isn't unlimited; rapid re-administration can cause receptor desensitization and reduced GH release on the second dose. The pre-workout protocol assumes GH itself drives acute training effects, which the literature doesn't strongly support; IGF-1 elevation takes hours and persists for days, so the timing of a single dose probably matters less than overall daily exposure.

Doses above 2 mg/day are described in some forum protocols (3 to 4 mg/day, sometimes higher). The FDA dose-ranging data found no incremental benefit above 2 mg, and IGF-1 levels can climb into ranges that raise concern about long-term safety.

What the body composition data actually shows

The strongest data on tesamorelin and body composition in any population comes from two trials.

Falutz et al., NEJM 2007. 412 HIV-positive patients with abdominal fat accumulation, randomized 2:1 to tesamorelin 2 mg/day or placebo for 26 weeks. The tesamorelin group lost 15.2% of visceral adipose tissue (VAT) on average, versus a 5% gain in placebo. Trunk fat decreased by 6.1%. Lean mass went up by 2.5%. Limb fat (subcutaneous fat) was unchanged. IGF-1 increased by 81%.

Falutz et al., J Clin Endocrinol Metab 2010. Patients from the original trial entered an extension phase. Those who continued tesamorelin for 52 weeks maintained their VAT reduction; those who crossed over to placebo regained much of the visceral fat by week 52.

For healthy adults, no comparable trials exist. A small unpublished cohort study and a few case series have looked at tesamorelin in non-HIV populations with central adiposity, but the data is too sparse to support firm dosing recommendations.

The takeaway: tesamorelin probably reduces visceral fat in a wider range of populations than just HIV-lipodystrophy, but the effect on subcutaneous fat (the kind most lifters want to drop) and lean mass (the kind most lifters want to add) is small in the published data. Expectations should be calibrated accordingly.

Side effects and IGF-1 elevation risk

The Falutz trials reported the following side effects more often in tesamorelin than placebo:

• Injection site reactions (erythema, pruritus, induration) in about 25% of patients
• Joint pain (arthralgia) in about 13%
• Limb pain in about 6%
• Peripheral edema in about 6%
• Hyperglycemia (modest fasting glucose elevation) in about 4 to 9%
• Headache in about 4%

The most clinically watchful signal is IGF-1 elevation. Tesamorelin raises IGF-1 by about 80% in HIV trial subjects. Sustained IGF-1 levels above the age-adjusted reference range have been associated, in epidemiologic studies, with increased risk of certain cancers (notably colorectal and prostate). The Falutz trials weren't long enough or large enough to test cancer outcomes directly.

Tesamorelin is contraindicated in:

• Active malignancy. GH-axis stimulation may accelerate tumor growth.
• Hypopituitarism, pituitary tumor, hypothalamic disease, or recent head injury. The mechanism depends on a functioning pituitary.
• Pregnancy. Adequate human safety data is not available.
• Known hypersensitivity to mannitol or to tesamorelin itself.

People with diabetes or glucose intolerance should monitor fasting glucose and HbA1c. GH-axis stimulation can worsen insulin resistance.

For more on weight-related conditions and medication interactions, see our comorbid condition guide.

Tesamorelin vs other GH secretagogues

Tesamorelin sits in a category of "GH secretagogues" alongside several other peptides used off-label in performance contexts.

Peptide	Mechanism	FDA status	Typical "bodybuilding" dose	Half-life
Tesamorelin	GHRH analog	Approved for HIV lipodystrophy	2 mg/day	~26 min (peptide); IGF-1 lasts days
Sermorelin	GHRH analog (29 AA)	Approved for pediatric GH deficiency (now discontinued in U.S. brand form)	200 to 500 mcg/day	~10 min
CJC-1295 (no DAC)	GHRH analog	Not FDA-approved	100 mcg 1 to 3x/day	~30 min
CJC-1295 with DAC	GHRH analog with albumin tag	Not FDA-approved	1 to 2 mg/week	6 to 8 days
Ipamorelin	Ghrelin mimetic / GHRP	Not FDA-approved	200 to 300 mcg 1 to 3x/day	~2 hours

Tesamorelin is unique in this category for being FDA-approved for an indication, having published Phase III data, and producing the largest single-peptide IGF-1 response. Sermorelin produces a milder response. CJC-1295 with DAC produces a sustained response but at the cost of losing pulsatility, which may reduce some of the physiological advantages of upstream stimulation.

The "blend" approach common in performance contexts (tesamorelin or CJC-1295 plus ipamorelin) hasn't been studied in controlled trials. The theoretical rationale is that GHRH analogs and ghrelin mimetics work on different pituitary cell mechanisms and may have additive effects. The empirical evidence is anecdotal. For more on related peptides, see our sermorelin overview.

Legal status and regulation

Tesamorelin (brand name Egrifta) is a prescription medication in the United States. Possession, distribution, or use without a valid prescription is illegal under federal law. It is not a controlled substance under the Controlled Substances Act, but it falls under the FDCA prescription drug provisions.

In late 2023 and 2024, the FDA increased enforcement against research chemical retailers and "peptide vendors" selling tesamorelin and similar peptides without prescriptions. Some products marketed as tesamorelin have been tested and found to contain different molecules, lower-than-labeled doses, or contaminants.

State medical boards have varied positions on prescribing tesamorelin off-label for body composition. Some boards consider it within the standard of care if appropriate workup is done. Others have disciplined providers for off-label peptide prescribing without an FDA-recognized indication. The legal landscape continues to evolve.

If you're considering tesamorelin and you have a clinical reason that may warrant it (visceral adiposity not responsive to diet and exercise, or suspected GH-axis dysfunction), a workup including baseline IGF-1, fasting glucose, lipid panel, and provider evaluation is a reasonable starting point. Self-prescribing or sourcing from research-chemical retailers carries both legal risk and product-quality risk.

Bloodwork to monitor

Patients on tesamorelin (whether for the FDA-approved HIV indication or off-label) typically have the following bloodwork before starting and periodically during use:

Test	Why it matters	Monitoring frequency
IGF-1	Tracks GH-axis response; flag if above age-adjusted upper limit	Baseline, 6 weeks, then every 3 to 6 months
Fasting glucose	GH stimulation can worsen insulin resistance	Baseline, 3 months, then every 6 months
HbA1c	Long-term glucose control	Baseline, 6 months
Lipid panel	GH effects on lipids	Baseline, 6 months
TSH and free T4	GH-axis interactions with thyroid	Baseline, annually
CBC, CMP	General health	Baseline, annually
PSA (men >40)	IGF-1 and prostate concerns	Baseline if applicable

If IGF-1 climbs into the upper quartile of the reference range, most clinicians reduce the dose. If it exceeds the upper limit of the reference range, most clinicians pause the medication and re-evaluate.

FAQ

What's the standard tesamorelin dose for bodybuilding? There is no clinically validated bodybuilding dose. The only FDA-approved dose is 2 mg subcutaneous daily for HIV-associated lipodystrophy. Forum protocols typically extrapolate this dose, sometimes splitting it into two 1 mg injections, but no controlled trials in healthy adults exist.

How much fat can I lose on tesamorelin? Published data in HIV-lipodystrophy patients shows about 15% reduction in visceral fat over 26 weeks at 2 mg/day. Subcutaneous fat (what most people see) was not significantly reduced in those trials. Healthy lean adults are unlikely to see large subcutaneous fat losses from tesamorelin alone.

Will tesamorelin build muscle? The HIV trials showed about 2.5% increase in lean mass over 26 weeks at 2 mg/day. That's modest. There's no published controlled data showing tesamorelin produces meaningful hypertrophy in healthy trained individuals beyond what training and protein intake alone produce.

How do I inject tesamorelin? Subcutaneous injection in the abdomen, rotating sites, with a U-100 insulin syringe. The peptide comes lyophilized (powdered) and is reconstituted with sterile water or bacteriostatic water before use. Reconstituted solution is refrigerated and used within 14 days.

What's the half-life of tesamorelin? About 26 minutes for the peptide itself in plasma. The IGF-1 response it triggers persists for about 24 hours, which is why daily dosing is the norm. CJC-1295 with DAC has a much longer half-life (6 to 8 days), but tesamorelin doesn't.

Is tesamorelin safer than synthetic HGH? The mechanism of upstream GHRH stimulation preserves pulsatility and the body's negative feedback loops, which theoretically reduces some risks of exogenous HGH. But "safer" depends on dose and duration. Sustained tesamorelin use can produce IGF-1 elevations comparable to moderate HGH doses, with similar long-term concerns.

Can I cycle tesamorelin? Cycling protocols (12 weeks on, 4 weeks off) exist but aren't supported by data. The Falutz extension data shows the body composition benefit is lost when tesamorelin is discontinued, so cycles will likely involve regaining visceral fat during off-periods.

Will tesamorelin cause water retention? Mild peripheral edema is reported in about 6% of users in clinical trials. It's usually self-limiting. People sensitive to GH-related edema (puffy hands, face, ankles) may notice it more pronouncedly.

Does tesamorelin affect blood sugar? Yes. GH stimulation slightly worsens insulin resistance. Trial data shows fasting glucose elevations of 4 to 9% over baseline. Diabetic patients and pre-diabetic patients should monitor closely.

How long until I see results? Visceral fat changes were detectable at 13 weeks in the Falutz trial and continued through 26 weeks. Lean mass changes were small but measurable at 26 weeks. Most users report subjective body composition shifts at 8 to 12 weeks.

Is tesamorelin legal to buy from research chemical sites? No. Tesamorelin is a prescription drug in the U.S. Sale or purchase without a valid prescription is illegal. Research chemical retailers operate in legal gray areas and product purity is unverified.

Should I get bloodwork before starting? Yes. Baseline IGF-1, fasting glucose, HbA1c, lipid panel, and a general physical workup are standard. Repeat IGF-1 at 6 weeks to confirm the GH axis is responding without overshooting.

Sources

1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-2370.
2. Falutz J, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22:1719-1728.
3. Falutz J, et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial. JAMA. 2010;304:272-280.
4. Stanley TL, et al. Effects of tesamorelin on visceral fat in HIV-infected patients: a meta-analysis of two randomized controlled trials. Clin Endocrinol Metab. 2011;96:E1517-E1525.
5. U.S. Food and Drug Administration. Egrifta (tesamorelin for injection) prescribing information.
6. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6:45-53.
7. Khorram O, et al. Effects of a 6-month treatment with a GHRH analog in normal aging men. J Clin Endocrinol Metab. 1997;82:1472-1479.
8. Veldhuis JD, et al. Endocrine and metabolic effects of GHRH analogs in older adults. J Clin Endocrinol Metab. 2009;94:973-981.
9. Liu H, et al. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med. 2008;148:747-758.
10. Holt RIG, Sönksen PH. Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol. 2008;154:542-556.
11. Renehan AG, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review. Lancet. 2004;363:1346-1353.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Egrifta is a registered trademark of Theratechnologies. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.